Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

Study:

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies

Rationale:

n/a

Purpose:

This is a Phase II, open-label, two strata, multicenter, prospective study of plerixafor-mobilized HLA-identical sibling allografts in recipients with hematological malignancies. This study will establish the safety and efficacy of subcutaneous plerixafor for this purpose.

Study Status: Recruiting

Recruiting:
n/a

Condition Intervention Phase
For Donors:
Related Donors Donating PBSC to a Family Member
For Recipients:
Acute Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Chronic Myelogenous Leukemia
Non-Hodgkin`s Lymphoma
Hodgkin`s Disease
Chronic Lymphocytic Leukemia
Drug: Plerixafor Phase 2

Verified by Center for International Blood and Marrow Transplant Research December, 2013

Sponsored by: Center for International Blood and Marrow Transplant Research
Information provided by: Center for International Blood and Marrow Transplant Research
ClinicalTrials.gov identifier: NCT01696461

Study Type: Interventional

Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio
United States

Steve Devine, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site